Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 16, 2005

View Archived Issues

Combining 5-HT6 and 5-HT2A antagonists improves both psychotic and cognitive deficits in rats

Conessine derivatives antagonize human H3 receptors and penetrate BBB

Novel CDK inhibitor from Roche

Apixaban enters phase II/III trials as a preventive therapy for venous and pulmonary thrombosis

Avalon and Novartis collaborate on drug discovery

Pharmacokinetic profile of NBI-12i in rats

Phase I study to begin for Cardio Vascu-Grow in diabetic wounds

Phase II protocol submitted for Davanat/5-FU in cholangiocarcinoma

Indaflex studied in phase II trial for osteoarthritis of the knee

Clearance for phase II study of topical interferon alpha-2b in ano-genital warts

Calcium-sensing receptor (CaSR) validated as a target for bladder dysfunction

Glucosylceramide synthase inhibitor suppresses tumor growth in vivo

Hybridon changes name to Idera

Abatacept demonstrates sustained efficacy in rheumatoid arthritis

Amantadine shows efficacy in preventing weight gain associated with olanzapine therapy

Bicifadine induces significant pain relief after bunionectomy

Pfizer completes acquisition of Vicuron

MedImmune to acquire Cellective Therapeutics

Phase II trial of TNX-355 for HIV recommended to continue

Alzhemed begins European phase III trial

Synta begins phase IIb trial of STA-5326 in active Crohn's disease

Private financing to support preclinical development of Riotech's IFN-alpha-8

Calpain inhibitors disclosed as potential agents for DMD/News in Context

Method of risk assessment for autism described in recent patent literature

Agents for arthritis and other inflammatory conditions revealed in patent literature

Plant extracts demonstrate antidiabetic activity

CTCE-0214 supports stem-cell expansion and engraftment

Bexel Pharmaceuticals presents new data on their antidiabetic candidates

Positive opinion issued for Naglazyme for MPS VI in Europe

NovoLog approved for use in children

FDA expands Neulasta label

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...